IN THE LITERATURE Is Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Combination Therapy Better Than Monotherapy and Safe in Patients With CKD?

[1]  R. Townsend,et al.  Is there added value to adding ARB to ACE inhibitors in the management of CKD? , 2009, Journal of the American Society of Nephrology : JASN.

[2]  B. Rutkowski,et al.  Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  P. Zamboli,et al.  Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  G. Bakris,et al.  Renin-angiotensin blockade and kidney disease , 2008, The Lancet.

[5]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[6]  J. McMurray ACE inhibitors in cardiovascular disease--unbeatable? , 2008, The New England journal of medicine.

[7]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[8]  A. Kshirsagar,et al.  Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  U. Wenzel,et al.  Aldosterone and progression of renal disease , 2008, Current opinion in nephrology and hypertension.

[10]  R. Kunz,et al.  Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the ReninAngiotensin System on Proteinuria in Renal Disease , 2008, Annals of Internal Medicine.

[11]  J. Kalus,et al.  Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta‐analysis , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[12]  J. Craig,et al.  Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. , 2006, The Cochrane database of systematic reviews.

[13]  K. Griffin,et al.  Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[14]  H. Clark,et al.  Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  G. Becker,et al.  Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[16]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[17]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[18]  H. Morita,et al.  RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial , 2003, The Lancet.

[19]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[20]  C. Schmid,et al.  Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. , 2001, Kidney international.

[21]  C. Schmid,et al.  Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease , 2001, Annals of Internal Medicine.